However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00. Carter Gould has given his Buy rating due to a combination of ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Although AbbVie IPO’s 11 years ago, it spun off from Abbott Laboratories which had a long history of paying and growing dividends, giving the AbbVie the requisite to be called a “dividend ...

HON:CAHoneywell International Inc.

AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics. The program also includes an ...

Dividend growth stocks offer a unique blend of reliability and growth potential, making them an ideal choice for long-term ...

Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia missed their primary endpoints. AbbVie’s two ...

Also, when you purchase shares of dividend stocks ... ongoing programs. AbbVie is competent enough to get around one of the most important patent cliffs in the industry's history and start growing ...